Acer Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $37.29 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- $1.26 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Acer Therapeutics Inc had its IPO on 2017-09-22 under the ticker symbol ACER.
The company operates in the Healthcare sector and Biotechnology industry. Acer Therapeutics Inc has a staff strength of 41 employees.
Shares of Acer Therapeutics Inc opened at $0.77 at the start of the last trading session i.e. 2023-03-22.
The stocks traded within a range of $0.7 - $0.79, and closed at $0.75.
This is a -5.18% slip from the previous day's closing price.
A total volume of 489,897 shares were traded at the close of the day’s session.
In the last one week, shares of Acer Therapeutics Inc have slipped by -55.09%.
Acer Therapeutics Inc's Key Ratios
Acer Therapeutics Inc has a market cap of $37.29 million, indicating a price to book ratio of 17.2561 and a price to sales ratio of 174.5231.
In the last 12-months Acer Therapeutics Inc’s revenue was $360000 with a gross profit of $1.26 million and an EBITDA of $-23698394. The EBITDA ratio measures Acer Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Acer Therapeutics Inc’s operating margin was -6603.02% while its return on assets stood at -62.07% with a return of equity of -472.99%.
In Q3, Acer Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Acer Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.4 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Acer Therapeutics Inc’s profitability.
Acer Therapeutics Inc stock is trading at a EV to sales ratio of 102.7606 and a EV to EBITDA ratio of -1.561. Its price to sales ratio in the trailing 12-months stood at 174.5231.
Acer Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $15.32 million
- Total Liabilities
- $20.79 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Acer Therapeutics Inc ended 2023 with $15.32 million in total assets and $0 in total liabilities. Its intangible assets were valued at $15.32 million while shareholder equity stood at $-12207317.00.
Acer Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $20.79 million in other current liabilities, 1637.00 in common stock, $-131362939.00 in retained earnings and $7.65 million in goodwill. Its cash balance stood at $6.38 million and cash and short-term investments were $6.38 million. The company’s total short-term debt was $1,510,571 while long-term debt stood at $6.57 million.
Acer Therapeutics Inc’s total current assets stands at $7.30 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0.00 compared to accounts payable of $4.69 million and inventory worth $0.
In 2023, Acer Therapeutics Inc's operating cash flow was $-4905.00 while its capital expenditure stood at $4905.
Comparatively, Acer Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Acer Therapeutics Inc stock is currently trading at $0.75 per share. It touched a 52-week high of $4.56 and a 52-week low of $4.56. Analysts tracking the stock have a 12-month average target price of $8.5.
Its 50-day moving average was $2.07 and 200-day moving average was $1.74 The short ratio stood at 0.84 indicating a short percent outstanding of 0%.
Around 1838.6% of the company’s stock are held by insiders while 3128.4% are held by institutions.
Frequently Asked Questions About Acer Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.